Quarterly ResultMay 12, 2026, 04:14 PM
Maze Therapeutics MZE829 Phase 2 positive; Q1 Net Loss $24.2M
AI Summary
Maze Therapeutics reported positive topline data from its Phase 2 HORIZON trial for MZE829 in broad AMKD, demonstrating a clinically meaningful reduction in proteinuria and supporting advancement to a pivotal trial in H1 2027. The company also announced plans to initiate two Phase 2 trials for MZE782 in PKU and CKD by mid-2026 and H2 2026, respectively. For Q1 2026, Maze reported a net loss of $24.2 million on $20.0 million in license revenue, and a strong balance sheet with $362.9 million in cash, cash equivalents, and marketable securities, projecting a cash runway into 2029.
Key Highlights
- MZE829 Phase 2 HORIZON trial showed 35.6% mean uACR reduction in broad AMKD.
- MZE829 pivotal trial in moderate AMKD without diabetes planned for H1 2027.
- MZE782 Phase 2 trials for PKU and CKD to start mid-2026 and H2 2026, respectively.
- Cash, cash equivalents, and marketable securities totaled $362.9M as of March 31, 2026.
- Expected cash runway extends into 2029, including $150M offering and $20M milestone.
- Q1 2026 license revenue was $20.0M, up from $0 in Q1 2025.
- Q1 2026 R&D expenses increased to $34.1M from $27.6M YoY.
- Q1 2026 net loss was $24.2M, or $0.45 per share.